CAJ | 학술논문

目的：探讨替吉奥合并奥沙利铂或多西他赛治疗晚期胃癌的近期疗效及安全性。方法90例未经治疗的晚期胃癌患者，随机分为研究组（替吉奥联合奥沙利铂）和对照组（替吉奥联合多西他赛），每组45例。2组均口服替吉奥胶囊40 mg/m2，2次/d，3周为l周期。其中研究组第1天联合奥沙利铂130 mg/m2静脉滴注，3周为l周期；对照组第1天联合多西他赛60 mg/m2静脉滴注，3周为1周期。2组均至少完成2个周期。比较治疗2周期后2组近期、远期疗效、不良反应和生活质量。结果研究组和对照组治疗6周有效率分别为55 W．6％和46．6％（χ2＝0．71， P ＞0．05）；疾病控制率分别为91．1％和84．4％（χ2＝0．93， P ＞0．05）。研究组和对照组mTTP分别为6．1、4．7个月（ t ＝1．842， P ＝0．069）；mOS分别为11．4、12．3个月（ t ＝0．896， P ＝0．387）；PFS分别为8．3、7．6个月（ t ＝1．273， P ＝0．206）；OS分别为11．6、10．4个月（ t ＝1．493， P ＝0．139）。研究组和对照组生存质量改善率分别为88．9％、80．0％（χ2＝1．35， P ＝0．245）。研究组与对照组发生贫血分别为46．7％、26．7％（χ2＝3．88， P ＝0．048）；手足综合征分别为17．8％、40．0％（χ2＝5．41， P ＝0．020）；肝功能异常分别为11．1％、37．8％（χ2＝8．66， P ＝0．003）。结论替吉奥联合奥沙利铂或者多西他赛，2种方案疗效相当，但替吉奥联合奥沙利铂的药物不良反应较少。
목적：탐토체길오합병오사리박혹다서타새치료만기위암적근기료효급안전성。방법90례미경치료적만기위암환자，수궤분위연구조（체길오연합오사리박）화대조조（체길오연합다서타새），매조45례。2조균구복체길오효낭40 mg/m2，2차/d，3주위l주기。기중연구조제1천연합오사리박130 mg/m2정맥적주，3주위l주기；대조조제1천연합다서타새60 mg/m2정맥적주，3주위1주기。2조균지소완성2개주기。비교치료2주기후2조근기、원기료효、불량반응화생활질량。결과연구조화대조조치료6주유효솔분별위55 W．6％화46．6％（χ2＝0．71， P ＞0．05）；질병공제솔분별위91．1％화84．4％（χ2＝0．93， P ＞0．05）。연구조화대조조mTTP분별위6．1、4．7개월（ t ＝1．842， P ＝0．069）；mOS분별위11．4、12．3개월（ t ＝0．896， P ＝0．387）；PFS분별위8．3、7．6개월（ t ＝1．273， P ＝0．206）；OS분별위11．6、10．4개월（ t ＝1．493， P ＝0．139）。연구조화대조조생존질량개선솔분별위88．9％、80．0％（χ2＝1．35， P ＝0．245）。연구조여대조조발생빈혈분별위46．7％、26．7％（χ2＝3．88， P ＝0．048）；수족종합정분별위17．8％、40．0％（χ2＝5．41， P ＝0．020）；간공능이상분별위11．1％、37．8％（χ2＝8．66， P ＝0．003）。결론체길오연합오사리박혹자다서타새，2충방안료효상당，단체길오연합오사리박적약물불량반응교소。
Objective To explore the short-term efficacy and safety of docetaxel combined with oxaliplatin or S-1 in the treatment of advanced gastric cancer .Methods Ninty cases of untreated patients with advanced gastric cancer were ran-domly divided into study group ( S-1 combined with oxaliplatin ) and control group ( S-1 combined with docetaxel ) ,45 cases in each group.The 2 groups were treated with S-1 capsule 40 mg/m2, bid, 3 weeks for one cycle.The study group’s first day’ s treatment were combined with oxaliplatin 130 mg/m2 intravenous drip, 3 weeks for one cycle;the control group’s first day’ s treatment were plus with docetaxel 60 mg/m2 intravenous drip, 3 weeks for 1 cycles.The 2 groups’ treatment was completed at least 2 cycles.Compared 2 groups’ recently, long-term efficacy, adverse reactions and quality of life after 2 cycle treat-ment.Results After 6 weeks treatment, the efficiency of study group and the control group ’ s were 55.6% and 46.6%(χ2 =0.71, P >0.05);disease control rate were 91.1% and 84.4% (χ2 =0.93, P >0.05).The study group and the control group’s mTTP were 6.1 and 4.7 months ( t =1.842, P =0.069); mOS were 11.4 and 12.3 months respectively (t =0.896, P =0.387);PFS were 8.3 and 7.6 months respectively ( t =1.273, P =0.206); OS were 11.6 and 10.4 months ( t =1.493, P =0.139).The study group and the control group ’s improvement of quality of life were 88.9% and 80.0%respectively (χ2 =1.35, P =0.245).The study group and control group ’s anemia were 46.7%and 26.7%(χ2 =3.88, P =0.048);hand foot syndrome were 17.8%and 40.0%respectively (χ2 =5.41, P =0.020);abnormal liver func-tion were 11.1%and 37.8%(χ2 =8.66, P =0.003).Conclusion S-1 combined with oxaliplatin or docetaxel , a consider-able effect of the two kinds of schemes , but S-1 combined with oxaliplatin has less adverse drug reaction .